Christopher Ogden - CytomX Therapeutics Principal Accounting
| CTMX Stock | USD 1.04 0.05 4.59% |
Insider
Christopher Ogden is Principal Accounting of CytomX Therapeutics
| Age | 40 |
| Address | 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 515 3185 |
| Web | https://www.cytomx.com |
Christopher Ogden Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Ogden against CytomX Therapeutics stock is an integral part of due diligence when investing in CytomX Therapeutics. Christopher Ogden insider activity provides valuable insight into whether CytomX Therapeutics is net buyers or sellers over its current business cycle. Note, CytomX Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell CytomX Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Ogden over three months ago Acquisition by Christopher Ogden of 75000 shares of CytomX Therapeutics at 1.49 subject to Rule 16b-3 | ||
Christopher Ogden over three months ago Acquisition by Christopher Ogden of 40000 shares of CytomX Therapeutics subject to Rule 16b-3 |
CytomX Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0233 % which means that it generated a profit of $0.0233 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.01 in 2024, whereas Return On Tangible Assets are likely to drop (0) in 2024. At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 87.2 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 19.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michelle Doig | Nuvation Bio | 46 | |
| CPA CPA | NextCure | 61 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Sandeep MD | Instil Bio | 55 | |
| Lieping MD | NextCure | 67 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Daniel Welch | Nuvation Bio | 63 | |
| Sumita JD | Instil Bio | 50 | |
| James Brady | Spero Therapeutics | N/A | |
| Angela MD | Spero Therapeutics | N/A | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| MBA MD | Spero Therapeutics | 43 | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| W Vernon | Nuvation Bio | 65 | |
Management Performance
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.0233 |
CytomX Therapeutics Leadership Team
Elected by the shareholders, the CytomX Therapeutics' board of directors comprises two types of representatives: CytomX Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CytomX. The board's role is to monitor CytomX Therapeutics' management team and ensure that shareholders' interests are well served. CytomX Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CytomX Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Head VP | ||
| JD Rowland, General VP | ||
| Danielle OlanderMoghadassian, Senior Officer | ||
| YuWaye MD, Senior Officer | ||
| Leslie Robbins, Senior Vice President - Intellectual Property | ||
| Sean DPHIL, Chairman CEO | ||
| Christopher Ogden, Principal Accounting | ||
| Marcia Belvin, Senior Officer | ||
| Chau MBA, Vice Communications | ||
| Hoyoung MD, Special Officer | ||
| Jamie Moore, VP Manufacturing | ||
| Dawn Benson, Senior Manufacturing | ||
| DPHIL DPhil, Chairman CEO |
CytomX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CytomX Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.0233 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | (44.19 M) | ||||
| Shares Outstanding | 78.12 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 72.58 % | ||||
| Number Of Shares Shorted | 5.67 M | ||||
| Price To Earning | (11.41) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.